Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for Evaluating Risk in Multiple Sclerosis

a risk assessment and multiple sclerosis technology, applied in the field of multiple sclerosis risk assessment methods and reagents, can solve problems such as persistent disability in young adults

Inactive Publication Date: 2010-08-12
GLYCOMINKS LTD
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Problems solved by technology

It is a common cause of persistent disability in young adults.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for Evaluating Risk in Multiple Sclerosis
  • Method for Evaluating Risk in Multiple Sclerosis
  • Method for Evaluating Risk in Multiple Sclerosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Anti-α-Glucose Based Glycan IgM Antibodies Predict Relapse Activity in Multiple Sclerosis After the First Presentation

Serum Samples

[0051]The results presented herein are from a retrospective study of frozen (−70° C.) and re-thawed serum samples collected from patients at the time of diagnostic work-up for their FP who were later diagnosed as RRMS. The control group included sera samples taken from patients with other neurological diseases (OND) that were stored around the same time from routine samples sent to the respective cerebrospinal fluid (CSF) diagnostic laboratories. Demographic and clinical data were obtained from hospital records. Inclusion criteria for MS samples were as follows: patient age (18-60 years) at time of sampling, follow-up for at least 4 years from blood sampling, and diagnosis of RRMS according to Poser criteria (Poser C M, et al. 1983 Ann Neurol, 13: 227-31). Samples meeting the above criteria were identified from one of two serum repositories located at th...

example 2

Panel of Anti-α-Glucose Based Glycan IgM Antibodies (Anti-GAGA2, Anti-GAGA3, Anti-GAGA4, and Anti-GAGA6) Predict Expanded Disability Status Scale Progression in Clinically Isolated Syndrome Patients Suggestive of Multiple Sclerosis

[0067]Prior to the invention, there was no specific serum based biomarker for the prognosis of Expanded Disability Status Scale (EDSS) progression in clinically isolated syndrome (CIS) patients suggestive of Multiple Sclerosis (MS). For patients with CIS suggestive of MS, there is a need to predict the patients with higher risk for rapid progression in EDSS score. As described in detail below, levels of IgM antibodies to a panel of four glucose-based glycans were analyzed for their ability to predict risk of rapid EDSS progression in CIS patients suggestive of MS within 5 years in patients treated early and those that received delayed treatment.

[0068]A prospective analysis was performed on 286 sera samples taken from CIS patients at baseline in the Betafer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis. The present invention is based, in part, upon the discovery that anti-glycan antibodies are useful in evaluating the risk of whether clinically isolated syndrome (CIS) patients suggestive of Multiple sclerosis (MS) will have a clinical relapse within, e.g., 24 months. The invention is also based upon the discovery that anti-glycan antibodies are useful for evaluating the risk of CIS patients suggestive of MS to have a rapid disease progression and accumulate disabilities, e.g., permanent disability, within a certain time frame, e.g., 5 years.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Ser. No. 61 / 152,168, filed Feb. 12, 2009, the contents of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis.BACKGROUND OF THE INVENTION[0003]Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system. It is a common cause of persistent disability in young adults. In patients suffering from MS, the immune system destroys the myelin sheath of axons in the brain and the spinal cord, causing a variety of neurological pathologies. In the most common form of MS, Relapsing-Remitting (RRMS), episodes of acute worsening of neurological function (exacerbations, attacks) are followed by partial or complete recovery periods (remissions) that are free of disease progression (stable).[0004]There is a clinical need for a simple serological as...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/02G01N33/68
CPCG01N33/6896G01N2800/56G01N2800/50G01N2800/285
Inventor DOTAN, NIRDUKLER, AVINOAM
Owner GLYCOMINKS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com